The primary objectives of the MATRIX program are to assess whether TRI or bivalirudin as compared , respectively , with transfemoral coronary intervention ( MATRIX access site ) or unfractionated heparin plus provisional glycoprotein IIb/IIIa inhibitors , ( MATRIX antithrombin ) decrease the 30-day incidence of an ischemic ( ie , death , myocardial infarction or stroke ) or an ischemic and bleeding composite end point across the whole spectrum of ACS patients , including clarifying the optimal duration of bivalirudin infusion after percutaneous coronary intervention ( MATRIX treatment duration ) .